<DOC>
	<DOCNO>NCT01215799</DOCNO>
	<brief_summary>This Phase II open-label study evaluate preliminary efficacy safety bafetinib administer 240 mg orally twice daily subject Hormone Refractory Prostate Cancer .</brief_summary>
	<brief_title>Study Bafetinib ( INNO-406 ) Treatment Patients With Hormone-Refractory Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Males age â‰¥18 year . Histologically confirm diagnosis adenocarcinoma prostate . Hormonerefractory prostate cancer progress despite androgen deprivation therapy result castrated level testosterone ( &lt; 50 ng/dL ) orchiectomy ; without evidence measurable evaluable disease . PSA increase define 2 consecutive rise ; first increase PSA occur minimum 1 week reference value ; increase PSA least 25 % reference value absolute PSA value &gt; 5 ng/mL . May receive 1 prior chemotherapy regimen . Prior immunomodulatory therapy ( sipuleucelt ( Provenge ) , interferon ) allow . Must take single agent LHRH agonist antagonist , unless previously underwent orchiectomy . ECOG performance status 02 . Able swallow pill . Able provide write , voluntary inform consent , comply trial procedure , accessibility site . Chemotherapy , antibody therapy , major surgery irradiation within 4 week study enrollment Exposure investigational agent within 30 day Screening Visit . No prior flutamide ( Eulexin ) ketoconazole use within 4 week , bicalutamide ( Casodex ) within 6 week nilutamide ( Nilandron ) within 6 week study enrollment . Use Quadramet therapy 2 month prior study enrollment Metastron ever . Prior treatment tyrosine kinase inhibitor . Subjects start bisphosphonate therapy within 4 week study enrollment exclude . Subjects treat stable dose bisphosphonate &gt; 4 week tumor still progress enrol study . Known CNS disease CNS metastases . History malignancy within last five year except curatively treat basal cell carcinoma superficial bladder cancer . Laboratory value : Screening serum creatinine great equal 1.5 x ULN , alanine aminotransferase ( ALT ) great 3 time upper limit normal , total bilirubin great 3 time upper limit normal , white blood cell ( WBC ) count &lt; 3500/mm3 , absolute neutrophil count &lt; 1500/mm3 , hematocrit level &lt; 35 % platelet &lt; 100,000/mm3 . History abnormal bleeding use anticoagulant therapy . Clinically evident congestive heart failure &gt; class II New York Heart Association ( NYHA ) guideline . Serious , clinically significant cardiac arrhythmia , define existence absolute arrhythmia ventricular arrhythmia classify Lown III , IV V. History MI within 6 month uncontrolled angina within 3 month . Severe and/or uncontrolled medical disease ( e.g . uncontrolled diabetes , chronic renal disease , chronic liver disease . Known HIV infection . Uncontrolled active , infection . Substance abuse condition might interfere subject 's participation study evaluation study result . Any condition opinion Investigator unstable could jeopardize subject 's participation study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Hormone Refractory Prostate Cancer</keyword>
	<keyword>HRPC</keyword>
</DOC>